Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has issued an update.
Jenscare Scientific Co., Ltd. announced the six-month clinical follow-up results for its LuX-Valve Plus transcatheter tricuspid valve replacement, demonstrating significant efficacy and safety for patients with large annulus. The study, presented at PCR London Valves 2025, highlights the device’s high success rate and improvements in patients’ cardiac function and quality of life, addressing a critical gap in treatment options for this patient group.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the medical device industry. The company specializes in developing innovative transcatheter heart valve replacement solutions, particularly targeting unmet clinical needs in patients with severe tricuspid regurgitation and high surgical risk.
Average Trading Volume: 768,217
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.67B
For a thorough assessment of 9877 stock, go to TipRanks’ Stock Analysis page.